A Case of Catatonia and Neuroleptic Malignant Syndrome Probably Associated with Antipsychotic in Korea

Olanzapine-Induced Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening idiosyncratic side effect resulting from neuroleptic drugs. NMS mainly occurs in patients treated with high-potency typical antipsychotics, but rarely caused by atypical antipsychotics. Although NMS is less common with atypical antipsychotic, but it seems that its incidence is rising due to increased administration of such drug...

Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription

OBJECTIVES To describe a case of neuroleptic malignant syndrome following antipsychotic treatment of catatonia, highlighting the potentially serious complications of this rare adverse drug reaction. METHODS We present a case report of a patient who developed this syndrome with various sequelae. RESULTS The patient developed neuroleptic after being treated with lorazepam and olanzapine for c...

Case report Olanzapine and ECT combined therapy in a refractory catatonic subtype schizophrenia patient with previous neuroleptic malignant syndrome episodes

Malignant Catatonia Warrants Early Psychiatric-Critical Care Collaborative Management: Two Cases and Literature Review

Malignant catatonia (MC) is a life-threatening manifestation which can occur in the setting of an underlying neuropsychiatric syndrome or general medical illness and shares clinical and pathophysiological features and medical comorbidities with the Neuroleptic Malignant Syndrome (NMS). The subsequent diagnosis and definitive therapy of MC are typically delayed, which increases morbidity and mor...

Intensive electroconvulsive therapy in drug resistant neuroleptic malignant syndrome - case report.

Neuroleptic malignant syndrome (NMS; ICD-10 code: G21.0) is a rare, although potentially life-threatening adverse reaction to antipsychotic drugs and other dopamine-modulating agents. Symptoms of NMS include: severe muscle rigidity, fever, autonomic instability, mental status changes and laboratory abnormallities (elevated serum levels of creatinine kinase, aldolase, transaminases, lactic acid ...